As Biocon prepares for a management transition past founder Kiran Mazumdar-Shaw, the Bengaluru-primarily based biopharmaceutical firm says years of funding in biosimilars, insulins and GLP-1 therapies at the moment are starting to translate into scale, working leverage and profitability.
Mazumdar-Shaw, who just lately introduced succession plans naming Claire Mazumdar, her niece, as her successor, stated the corporate has accomplished the heavy funding cycle wanted to construct its biosimilars platform and is now positioned to monetise these investments.
“Succession planning is all the time a really essential half to make sure that there’s good enterprise management by way of continuity of the imaginative and prescient and the strategic intent,” Mazumdar-Shaw informed Enterprise Right now, including that she had been grooming Claire for the function for a while. She described her successor as somebody able to “constructing an organization”, “managing threat” and delivering sturdy stakeholder engagement after efficiently constructing Bicara Therapeutics right into a Nasdaq-listed firm valued at over $1 billion.
The management change comes as Biocon consolidates its companies into what it calls “one unified world biopharma platform”, following the combination of its biosimilars, generics formulations and APIs companies. The corporate says the combination offers it a stronger steadiness sheet, improved capital allocation and a wider world business footprint.
MUST READ: Biocon will get a successor: Why Kiran Mazumdar-Shaw has chosen Claire Mazumdar
For Mazumdar-Shaw, the timing is linked carefully to the chance rising in biosimilars globally. “There are going to be $300 billion value of biologics which are going to lose patent safety over the next 10 years,” she stated. “To compete within the biosimilars enterprise, you want a pipeline, scale by way of each R&D and manufacturing, and a really sturdy business engine. Biocon has all of that.”
Mazumdar-Shaw believes Biocon’s early-mover benefit, built-in manufacturing mannequin and business scale place it otherwise from newer entrants relying on outsourcing and in-licensing fashions. She stated Biocon now has a 20-product biosimilars pipeline spanning marketed merchandise, close to-launch property and improvement-stage candidates.
Biocon’s biologics enterprise stays the corporate’s largest growth engine. The biosimilars phase reported income of Rs 10,431 crore in FY26, up 16% year-on-year, whereas EBITDA for the phase rose 40% on an adjusted foundation to Rs 2,751 crore. The enterprise now contributes greater than 60% of consolidated income.
The corporate stated the enterprise benefited from stronger uptake in superior markets, together with the US, alongside current launches and higher working leverage. Its biosimilars portfolio expanded through the 12 months with launches of Bosaya and Aukelso, the Denosumab biosimilars referencing Prolia and Xgeva within the US market.
MUST READ: Biocon bets on world markets as rivals battle India’s semaglutide worth warfare
Mazumdar-Shaw stated the US market itself has advanced considerably since Biocon first entered the phase. “Biosimilar adoption is getting higher. There may be larger familiarity and credibility that biosimilars have within the US,” she stated, noting that Biocon merchandise are gaining market share throughout oncology, immunology and insulin therapies.
Insulins and GLP-1 therapies are rising as one other strategic growth space for the corporate. Biocon has already launched liraglutide in Europe and the US and is making ready for semaglutide launches in rising markets.
“We’d be the one firm that has a portfolio of insulins on one facet and GLP-1s on the opposite,” Mazumdar-Shaw stated. “We’re right here to not win a dash, however to win a marathon.”
The corporate believes the mixture of insulin capabilities and GLP-1 manufacturing integration may create a protracted-time period aggressive benefit as obesity and diabetes therapies increase globally. Biocon drew parallels with earlier strategic bets it made in statins and immunosuppressants, the place it will definitely gained dominant market positions.
Importantly for traders, Biocon says the big capital expenditure cycle is now largely behind it. The corporate has already expanded manufacturing capability throughout biosimilars, insulins, peptides and advanced generics. The main target now could be on utilisation, margin enlargement and return on capital employed.
MUST READ: Weight-loss jabs like Ozempic, Mounjaro can slim you quick—however medical doctors warn of actual dangers
“There isn’t a extra massive-ticket capex to be spent going ahead,” Mazumdar-Shaw stated. “That gives us the chance to actually maintain rising plant utilisation and then generate extra profitability because of that.”
Biocon has additionally highlighted deleveraging and steadiness-sheet strengthening as key priorities. Its earnings presentation described FY26 as “a transparent inflection level”, marking the shift from integration and funding to “execution and worth creation”.
Shreehas Tambe, who took cost as CEO and Managing Director of Biocon from April 1, 2026, stated the corporate is now transferring from the “Protect” section of its technique to a “Consolidate” section targeted on sustainable growth.
The generics enterprise, in the meantime, confirmed enchancment pushed by generic liraglutide launches in Europe and regulatory approvals within the US and Australia. The corporate secured US FDA approval for generic liraglutide masking each diabetes and weight-administration indications through the quarter.
Biocon’s CRDMO arm, Syngene Worldwide, posted modest growth amid weak spot from a big biologics shopper, although the corporate stated the underlying enterprise remained secure. Syngene prolonged its partnership with Bristol Myers Squibb by way of 2035 and expanded its antibody-drug conjugate capabilities through the 12 months.
MUST READ: Dr. Reddy’s, Nestlé Well being Science launch vitamin product for sufferers on obesity drugs
For FY26, Biocon reported consolidated whole earnings of Rs 17,270 crore, up 14% year-on-year, whereas working income rose 13% to Rs 16,927 crore after adjusting for one-time generic lenalidomide gross sales in FY25. EBITDA stood at Rs 3,798 crore with margins bettering to 22%, whereas internet revenue earlier than distinctive gadgets rose sharply to Rs 436 crore from Rs 103 crore a 12 months earlier on an adjusted foundation.
Source link
#Kiran #Mazumdar #Shaw #plans #succession #Biocon #bets #biosimilars #obesity #drugs #growth #wave #BusinessToday
